Ultragenyx to Attend Investor Conferences This September
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 29 2025
0mins
Should l Buy RARE?
Source: Newsfilter
Upcoming Investor Conferences
- Cantor Global Healthcare Conference: Ultragenyx will participate on September 4, 2025, with Dr. Eric Crombez and CFO Howard Horn engaging in a fireside chat and hosting one-on-one meetings.
- Morgan Stanley 23rd Annual Global Healthcare Conference: Scheduled for September 9, 2025, Dr. Crombez will again participate in a fireside chat and hold one-on-one meetings.
- Bank of America Global Healthcare Conference: This event will take place on September 23, 2025, in London, where Dr. Crombez will participate in a fireside chat and conduct one-on-one meetings.
Company Overview
- Focus on Rare Diseases: Ultragenyx Pharmaceutical Inc. specializes in developing and commercializing therapies for serious rare and ultra-rare genetic diseases, aiming to address high unmet medical needs.
- Management Expertise: The company is led by a team experienced in rare disease therapeutics, emphasizing efficient drug development to deliver safe and effective therapies urgently.
- Diverse Portfolio: Ultragenyx has a range of approved therapies and product candidates targeting diseases that lack existing treatments.
Additional Information
- Webcast Availability: Live and archived webcasts of the fireside chats will be accessible on the company's website, providing further insights into their discussions and strategies.
- Contact Information: Investors can reach out to Joshua Higa at Ultragenyx for inquiries via email at ir@ultragenyx.com.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RARE
Wall Street analysts forecast RARE stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 23.500
Low
35.00
Averages
61.65
High
120.00
Current: 23.500
Low
35.00
Averages
61.65
High
120.00
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ultragenyx Strategic Restructuring and Product Launch Outlook
- Product Launch Outlook: Ultragenyx CEO Emil Kakkis indicated that the upcoming year marks a pivotal moment with two potential product launches and a crucial data readout, which could significantly accelerate the company's commercial revenue trajectory, highlighting its strategic importance in the rare disease sector.
- FDA Update: The company disclosed in its earnings report that it received an Incomplete Response Letter from the FDA regarding its UX111 gene therapy application, requesting additional supportive documentation; despite this setback, analyst William Blair believes the issue will be resolved promptly, reflecting market confidence in the product.
- Earnings Snapshot: Ultragenyx reported a fourth-quarter loss of $1.29 per share, missing the consensus estimate of $1.14, yet its sales of $207 million exceeded expectations of $196.97 million, showcasing the company's revenue growth potential amidst challenges.
- Strategic Restructuring Plan: The company announced a 10% workforce reduction affecting approximately 130 employees to cut operating expenses and align resources with high-impact opportunities, aiming for profitability by 2027, which underscores its focus on cost discipline and future profitability.
See More
Ultragenyx Pharmaceutical Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is facing a securities fraud class action lawsuit for actions taken between August 3, 2023, and December 26, 2025, with investors having until April 6, 2026, to seek lead plaintiff status, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that the company misled investors by failing to disclose risks associated with its drug setrusumab, particularly regarding the Phase III Orbit study's potential failure to achieve a statistically significant reduction in annualized fracture rate, which could negatively impact stock prices.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation, highlighting the potential financial liabilities and reputational damage the company may face due to these allegations.
- Legal Process: Investors can apply to be lead plaintiffs by April 6, 2026, or choose to remain absent class members, illustrating the complexities and potential impacts of legal proceedings on investor rights and company operations.
See More
Class Action Lawsuit Announced Against Ultragenyx Pharmaceutical Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Ultragenyx Pharmaceutical stock between August 3, 2023, and December 26, 2025, alleging that the company concealed critical information regarding clinical trial results, leading shareholders to buy at inflated prices.
- Compensation Mechanism: Investors may be entitled to compensation without any out-of-pocket costs through a contingency fee arrangement, significantly reducing the financial burden on participants in the class action.
- Details of the Lawsuit: The lawsuit claims that Ultragenyx made false statements regarding the efficacy of setrusumab in its Phase III Orbit and Cosmic studies, asserting that while the drug increased bone density, it did not correlate with a decrease in fracture rates, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, underscoring its expertise and experience in handling such cases.
See More
Ultragenyx Pharmaceutical Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Ultragenyx Pharmaceutical and certain officers, seeking damages for investors who purchased securities between August 3, 2023, and December 26, 2025, reflecting significant investor dissatisfaction with the company's transparency.
- Allegations of False Statements: The complaint alleges that throughout the class period, defendants made false and/or misleading statements and failed to disclose risks associated with the Phase III Orbit study's results, potentially leading investors to misjudge the company's prospects.
- Investor Action Deadline: Affected investors have until April 6, 2026, to request to be appointed as lead plaintiff in the case, indicating the urgency and importance of investor participation in the legal process for potential recovery.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, underscoring its expertise in upholding market integrity and investor rights.
See More
Ultragenyx Pharmaceutical Class Action Update
- Lawsuit Timeline: Robbins Geller law firm announced that purchasers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock must seek lead plaintiff status by April 6, 2026, providing a clear legal framework for investors to act.
- False Statement Allegations: The lawsuit alleges that Ultragenyx and its executives made false or misleading statements during the class period from August 3, 2023, to December 26, 2025, failing to disclose risks associated with their Osteogenesis Imperfecta (OI) study, misleading investors about the company's prospects.
- Stock Price Volatility: Following the July 9, 2025, announcement that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock plummeted over 25%; further, on December 29, 2025, the announcement of study failures led to an additional 42% drop, reflecting extreme market pessimism regarding the company's future.
- Lead Plaintiff Selection: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Ultragenyx stock during the class period can seek lead plaintiff status, allowing them to represent other investors in the lawsuit and providing an opportunity for potential recovery.
See More
Class Action Lawsuit Reminder Against Ultragenyx Pharmaceutical Inc.
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for violations of securities laws during the period from August 3, 2023, to December 26, 2025, urging affected investors to contact the firm before April 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Ultragenyx made false and misleading statements regarding its understanding of the effects of its drug candidate on Osteogenesis Imperfecta (OI) patients, leading to an erroneous optimistic outlook among investors and impacting market confidence.
- Clinical Trial Failure: The company failed to achieve a statistically significant reduction in annualized fracture rate (AFR) in the Phase III ORBIT study, revealing the falsity and misleading nature of its public statements, which resulted in investor losses once the truth was disclosed.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, showcasing the firm's expertise in representing investors in securities class action lawsuits globally.
See More
Ultragenyx Strategic Restructuring and Product Launch Outlook
- Product Launch Outlook: Ultragenyx CEO Emil Kakkis indicated that the upcoming year marks a pivotal moment with two potential product launches and a crucial data readout, which could significantly accelerate the company's commercial revenue trajectory, highlighting its strategic importance in the rare disease sector.
- FDA Update: The company disclosed in its earnings report that it received an Incomplete Response Letter from the FDA regarding its UX111 gene therapy application, requesting additional supportive documentation; despite this setback, analyst William Blair believes the issue will be resolved promptly, reflecting market confidence in the product.
- Earnings Snapshot: Ultragenyx reported a fourth-quarter loss of $1.29 per share, missing the consensus estimate of $1.14, yet its sales of $207 million exceeded expectations of $196.97 million, showcasing the company's revenue growth potential amidst challenges.
- Strategic Restructuring Plan: The company announced a 10% workforce reduction affecting approximately 130 employees to cut operating expenses and align resources with high-impact opportunities, aiming for profitability by 2027, which underscores its focus on cost discipline and future profitability.
See More
Ultragenyx Pharmaceutical Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is facing a securities fraud class action lawsuit for actions taken between August 3, 2023, and December 26, 2025, with investors having until April 6, 2026, to seek lead plaintiff status, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that the company misled investors by failing to disclose risks associated with its drug setrusumab, particularly regarding the Phase III Orbit study's potential failure to achieve a statistically significant reduction in annualized fracture rate, which could negatively impact stock prices.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation, highlighting the potential financial liabilities and reputational damage the company may face due to these allegations.
- Legal Process: Investors can apply to be lead plaintiffs by April 6, 2026, or choose to remain absent class members, illustrating the complexities and potential impacts of legal proceedings on investor rights and company operations.
See More
Class Action Lawsuit Announced Against Ultragenyx Pharmaceutical Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Ultragenyx Pharmaceutical stock between August 3, 2023, and December 26, 2025, alleging that the company concealed critical information regarding clinical trial results, leading shareholders to buy at inflated prices.
- Compensation Mechanism: Investors may be entitled to compensation without any out-of-pocket costs through a contingency fee arrangement, significantly reducing the financial burden on participants in the class action.
- Details of the Lawsuit: The lawsuit claims that Ultragenyx made false statements regarding the efficacy of setrusumab in its Phase III Orbit and Cosmic studies, asserting that while the drug increased bone density, it did not correlate with a decrease in fracture rates, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, underscoring its expertise and experience in handling such cases.
See More
Ultragenyx Pharmaceutical Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Ultragenyx Pharmaceutical and certain officers, seeking damages for investors who purchased securities between August 3, 2023, and December 26, 2025, reflecting significant investor dissatisfaction with the company's transparency.
- Allegations of False Statements: The complaint alleges that throughout the class period, defendants made false and/or misleading statements and failed to disclose risks associated with the Phase III Orbit study's results, potentially leading investors to misjudge the company's prospects.
- Investor Action Deadline: Affected investors have until April 6, 2026, to request to be appointed as lead plaintiff in the case, indicating the urgency and importance of investor participation in the legal process for potential recovery.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, underscoring its expertise in upholding market integrity and investor rights.
See More
Ultragenyx Pharmaceutical Class Action Update
- Lawsuit Timeline: Robbins Geller law firm announced that purchasers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock must seek lead plaintiff status by April 6, 2026, providing a clear legal framework for investors to act.
- False Statement Allegations: The lawsuit alleges that Ultragenyx and its executives made false or misleading statements during the class period from August 3, 2023, to December 26, 2025, failing to disclose risks associated with their Osteogenesis Imperfecta (OI) study, misleading investors about the company's prospects.
- Stock Price Volatility: Following the July 9, 2025, announcement that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock plummeted over 25%; further, on December 29, 2025, the announcement of study failures led to an additional 42% drop, reflecting extreme market pessimism regarding the company's future.
- Lead Plaintiff Selection: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Ultragenyx stock during the class period can seek lead plaintiff status, allowing them to represent other investors in the lawsuit and providing an opportunity for potential recovery.
See More
Class Action Lawsuit Reminder Against Ultragenyx Pharmaceutical Inc.
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for violations of securities laws during the period from August 3, 2023, to December 26, 2025, urging affected investors to contact the firm before April 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Ultragenyx made false and misleading statements regarding its understanding of the effects of its drug candidate on Osteogenesis Imperfecta (OI) patients, leading to an erroneous optimistic outlook among investors and impacting market confidence.
- Clinical Trial Failure: The company failed to achieve a statistically significant reduction in annualized fracture rate (AFR) in the Phase III ORBIT study, revealing the falsity and misleading nature of its public statements, which resulted in investor losses once the truth was disclosed.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, showcasing the firm's expertise in representing investors in securities class action lawsuits globally.
See More
